In his weekly clinical update, Dr. Griffin discusses progress toward measles elimination, risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune-suppressive drugs, symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals, late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial, higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19, recombinant C1 inhibitor in the prevention of severe COVID-19, and Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Progress toward measles elimination (CDC)
• Risk of severe COVID-19 despite vaccination in patients using immune-suppressive drugs (TID)
• Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to untreated individuals (CID)
• Late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial (JID)
• Higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19 (JAMA)
• Recombinant C1 inhibitor in the prevention of severe COVID-19 (FII)
• Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with SARS-CoV-2 disease course (BMC)
• Contribute to our MicrobeTV fundraiser at PWB 37:55
• Letters read on TWiV on TWiV 1062 38:16
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]